MedPath

Clinical and Dermoscopic evaluation of effectiveness of Metformin vs Pioglitazone in Acanthosis Nigricans.

Phase 4
Conditions
Health Condition 1: L83- Acanthosis nigricans
Registration Number
CTRI/2023/01/048858
Lead Sponsor
KLE Academy of Higher Education and Research - KLE University Grant
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

•Adult patients (>=18 years) with acanthosis nigricans attending the outpatient department of dermatology in KLE Prabhakar Kore Hospital

•Patients from whom written informed consent is obtained

Exclusion Criteria

•Patients already taking any oral hypoglycemic drug.

•Patient diagnosed as Type 1 Diabetes Mellitus

•Patient diagnosed as Drug induced AN

•Patients diagnosed as AN due to known malignancy

•Pregnant and lactating mothers

•Known allergic reaction to either Metformin or Pioglitazone

•Contraindicated for taking metformin or Pioglitazone

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath